PDL BioPharma (NASDAQ:PDLI) was downgraded by research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued on Tuesday.
A number of other analysts have also weighed in on PDLI. Cowen reiterated a “hold” rating and issued a $3.00 price objective on shares of PDL BioPharma in a research note on Friday, October 27th. ValuEngine upgraded shares of PDL BioPharma from a “hold” rating to a “buy” rating in a research note on Saturday, November 25th. Finally, Zacks Investment Research lowered shares of PDL BioPharma from a “buy” rating to a “hold” rating in a research note on Monday, January 8th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $3.33.
PDL BioPharma (NASDAQ:PDLI) opened at $2.48 on Tuesday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.10 and a current ratio of 3.16. PDL BioPharma has a 52 week low of $1.96 and a 52 week high of $3.55. The stock has a market cap of $382.76, a P/E ratio of 4.96 and a beta of 0.48.
TRADEMARK VIOLATION WARNING: This piece was first posted by Week Herald and is the property of of Week Herald. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The original version of this piece can be viewed at https://weekherald.com/2018/02/15/bidaskclub-downgrades-pdl-biopharma-pdli-to-strong-sell.html.
About PDL BioPharma
PDL BioPharma, Inc seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company’s segments include income generating assets and product sales.
Receive News & Ratings for PDL BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDL BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.